E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hypoglycemia associated with congenital hyperinsulinism |
|
E.1.1.1 | Medical condition in easily understood language |
Low blood glucose levels associated with abnormally high level of insulin due to a specific birth defect |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10077227 |
E.1.2 | Term | Hyperinsulinemic hypoglycemia |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020644 |
E.1.2 | Term | Hyperinsulinism NOS |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061211 |
E.1.2 | Term | Hyperinsulinism |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10022484 |
E.1.2 | Term | Insulin hypoglycaemia |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and clinical pharmacology of XOMA 358 in patients with hypoglycemia associated with congenital hyperinsulinism (HI). |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provide written informed consent and, as applicable, assent, before any study specific procedures are performed
2. Aged 12 to 65 years at Screening
3. Body mass index < 35 kg/m2 for patients aged 18 years and above and, for patients aged less than 18 years, BMI < 95% percentile for age
4. An established clinical diagnosis, with or without a genetic diagnosis, of congenital hyperinsulinism
5. Documented hypoglycemia (blood glucose < 60 mg/dL [< 3.33 mM]) during 2 monitored fasts during screening. Patients with blood glucose levels ≥ 60 mg/dL (≥ 3.33 mM) but who demonstrate a clinically meaningful decrease in blood glucose in conjunction with symptoms during the monitored fasts may be enrolled upon discussion and agreement between the Investigator and the Sponsor.
6. In the opinion of the Investigator, can be safely washed out of background medications used to treat HI
7. Hepatic ultrasound at Screening without clinically significant findings or evidence of peliosis hepatis
8. For female patients of childbearing potential, a negative serum pregnancy test
9. For female patients with reproductive potential (ie, fertile, following menarche and until becoming post-menopausal unless permanently sterile), a willingness to use highly effective* contraceptive measures adequate to prevent a new pregnancy for at least 3 months after administration of study drug. For women with reproductive potential who use a hormonal method of contraception, concurrent use of a second (barrier) method is recommended.
(*Highly effective methods of birth control are defined as those that alone or in combination result in a low failure rate [ie, less than 1% per year] when used consistently and correctly [eg, implants, injectables, oral contraceptives, some intrauterine devices, bilateral tubal occlusion, true sexual abstinence in line with the preferred and usual lifestyle of the patient, or vasectomized partner.]) |
|
E.4 | Principal exclusion criteria |
1. Any out-of-range laboratory value at Screening that has not been reviewed, approved, and documented as not clinically significant by the Investigator, except for the following liver function test exclusions:
- total bilirubin ≥ 1.5X upper limit of normal
- ALT, AST, or ALP ≥ 2X upper limit of normal
2. Use of any agent, such as diazoxide, octreotide, chronic systemic glucocorticoids, or β agonists, that may affect glucose metabolism. Such agents will be washed out before dosing. Topical, inhaled, and intranasal corticosteroids at doses that are unlikely to affect glucose homeostasis and corticosteroids for ophthalmic use are permitted.
3. Use of any long-acting somatostatin analogs or glucose-affecting medications that require > 72 hour washout
Note: Patients who are on a stable dose and regimen of a long-acting somatostatin analog and meet inclusion criterion number 5 for hypoglycemia during Screening may remain on such treatment and be enrolled into the study upon discussion and agreement between the Investigator and the XOMA Medical Monitor.
4. History of malignancy within 3 years before Screening other than carcinoma in situ of the cervix or adequately treated nonmetastatic squamous or basal cell carcinoma of the skin.
5. History of seropositivity for HIV antibody, hepatitis B, or hepatitis C antibody
6. Major general surgery within 3 months before Screening or anticipated during the study period
7. Known allergy or sensitivity to XOMA 358 or any component of the study drug
8. Treatment with an investigational drug or device within 30 days or 5 half-lives of the investigational drug before Day 1, whichever is longer. Participation in registries and purely diagnostic studies is allowed.
9. Female patients who are pregnant, planning to become pregnant during the course of the study, have recently delivered (within 3 months before Screening), or are breast-feeding
10. Male patients who are planning a pregnancy with a female partner during the course of the study or within 4 months after administration of study drug
11. Any organ condition, concomitant disease (eg, psychiatric illness, severe alcoholism, or drug abuse, cardiac, hepatic, or kidney disease), or other abnormality that itself, or the treatment of which, could interfere with the conduct of the study (eg, may affect absorption, distribution, metabolism, or elimination of the study drug) or that, in the opinion of the Investigator and/or Sponsor’s medical monitor, would pose an unacceptable risk to the patient in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Biological (analyses for each dose):
• Glucose AUC24
• Cumulative time blood glucose < 70 mg/dL (< 3.89 mM)
• Fasting and postprandial glucose, insulin, c-peptide
• Time to hypoglycemia during provocation (< 60 mg/dL [< 3.33 mM])
• Frequency of hypoglycemic events (< 60 mg/dL [< 3.33 mM])
• Concomitant treatment/medications used during rescue
Additional analyses will be performed, as appropriate.
Safety:
Safety will be assessed through an examination of the incidence, severity, and type of treatment-emergent adverse events and changes in vital signs, physical examination results, laboratory test results, ECG, hepatic ultrasound, glucose monitoring via a bedside glucometer, infusion site reaction, and use of concomitant medications and concomitant treatment from baseline to specified time points throughout the trial. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Measured at various time points (see schedule of events) |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |